Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Introduces AdvanceBio Peptide Mapping Columns

Published: Monday, May 13, 2013
Last Updated: Monday, May 13, 2013
Bookmark and Share
New HPLC and HILIC solutions enable faster, more robust analysis in biopharmaceutical discovery.

Agilent Technologies Inc. has introduced the latest updates to its AdvanceBio family of columns.

The new AdvanceBio Peptide Mapping BioHPLC and ZORBAX RRHD 300-HILIC columns are designed to deliver exceptional performance for the separation, characterization and analysis of a wide range of proteins, monoclonal antibodies, peptides and additional biologics.

Each of these columns enables users to achieve the highest-resolution results, faster than ever before.

“We are excited to introduce these valuable new columns to our pharmaceutical customers and other life science researchers seeking ever-greater analytical sensitivity and speed,” said Anne Jones, Agilent’s vice president and general manager for the chemistries business.

Jones continued, “These products are an example of our ongoing commitment to advancing accuracy and productivity in biochromatography.”

The new AdvanceBio Peptide Mapping column can rapidly determine the primary protein structure and identify modifications with unparalleled speed and sensitivity.

In fact, it can produce exceptional analytical results two to three times faster than conventional peptide mapping with fully porous HPLC columns, which can take up to 60 minutes.

Each batch of AdvanceBio mapping media is tested with a rigorous peptide mix to ensure suitability and reproducibility, enabling the identification of key peptides in complex peptide maps.

All available columns are stable to 600-bar, enabling maximum UHPLC instrument performance. They also deliver exceptional performance with legacy 400-bar instruments.

Applications

The AdvanceBio Peptide Mapping column is excellent for highly complex peptide mapping and will provide 100 percent sequence coverage of many protein digests, including rhEPO with 45 glycopeptide matches.

These features are explored in the application note, High-Resolution Glycopeptide Mapping of EPO Using an Agilent AdvanceBio Peptide Mapping Column.

The ZORBAX RRHD 300-HILIC columns are the only sub 2-μm, 300Å HILIC columns available today. They are designed specifically for users seeking faster, higher-resolution separation of peptides, polar glycopeptides, proteins, antibodies, conjugates, new biological entities and biopharmaceuticals.

Hydrophilic interaction liquid chromatography is designed to resolve hydrophilic glycopeptide variants. It also provides excellent peak shape for polar glycopeptides that have limited retention and resolution with reversed-phased columns.

For 1.8 μm particles, the ZORBAX RRHD 300-HILIC columns enable rapid analysis and 1200-bar stability with exceptional accuracy. They provide orthogonal and complementary separations to reversed-phase HPLC.

These features are explored in the application note, Analysis of Erythropoietin Glycopeptides and Glycoforms by HILIC and RP Chromatography.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
PerkinElmer supplies chips for Agilent's popular 2100 Bioanalyzer system.
Thursday, January 21, 2016
Agilent, Singapore Institute Collaborate
Agilent Technologies and Singapore's Bioprocessing Technology Institute today announced a collaboration to develop new analytical approaches to specific protein-linked sugar compounds.
Wednesday, July 15, 2015
Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Utilizing Fast HPLC Screening Methods for the Detection of Steroids
Analysis of steroids improved by choosing the optimal HPLC column for the separation.
Saturday, January 17, 2015
How to Achieve High-Speed, High-Resolution Glycan Mapping for mAb Characterization
The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern.
Monday, December 22, 2014
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent Announces Agreement with Picometrics Technologies
Agilent to provide Picometrics' biopharmaceutical customers with combined solutions for capillary electrophoresis (CE), laser induced fluorescence (LIF) detection and mass spectrometry.
Friday, January 17, 2014
Agilent, University of Rouen and A*STAR’s Bioprocessing Technology Institute to Collaborate
The collaborations aims to further innovation in biopharmaceuticals and glycomics through developing tools to effectively analyze biologics and vaccines.
Thursday, May 23, 2013
Agilent Technologies, University of Rouen and A*STAR’s Bioprocessing Technology Institute Collaborate
Organisations will work together to further innovation in biopharmaceuticals and glycomics.
Thursday, May 23, 2013
Agilent Technologies Introduces Verified Dissolution Components for Pharmaceutical Market
Agilent Technologies Inc. introduced a new series of verified dissolution components, including molded vessels as well as paddle and basket shafts.
Wednesday, May 15, 2013
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Merck-Serono Adopts Agilent Technologies’ Electronic Lab Notebook for Biology Research
Agilent Technologies Inc. have announced that Merck-Serono, a division of Merck KGaA, Darmstadt, Germany, has selected the Agilent OpenLAB Electronic Lab Notebook (ELN) to enhance scientific collaboration globally throughout R&D for finding new small molecules and biopharmaceuticals.
Tuesday, November 23, 2010
Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!